ASPIRE Awards
Funding Amount
Not stated
Deadline
Deadline not published
Grant Type
Foundation
Can we apply?
Check your organization against each line. Taken from the listing; confirm with the funder's guidelines.
Eligible organizations
- Co-investigators are permitted
Other requirements
- _You can learn more about this opportunity by visiting the funder's [website](https://themarkfoundation.org/aspire/)._
- ASPIRE Awards support research worldwide, and collaborations are within the scope of the funding mechanism
- Principal investigators must be independent researchers at their respective institutions
- The budget limit includes both direct and indirect costs, with indirect costs not to exceed 10% of the direct costs
Overview
_NOTE: Funder does not run an open RFP on a regular basis with this program._**
Recognizing the obstacles that prevent scientific advances from improving patient outcomes, we maintain a nimble, high-impact approach to funding basic and translational cancer research that bridges the gap between bench and bedside through grants and venture investments.
ASPIRE Award
The Mark Foundation for Cancer Research ASPIRE Awards support innovative ideas that have the potential to solve high-impact problems in cancer research, but may not have extensive – or any – preliminary supporting data.
ASPIRE Awards enable high-risk, high-reward projects to answer key feasibility and proof-of-concept questions and arrive at critical project inflection points in an accelerated time frame. ASPIRE Awards support work from bench to bedside, and special consideration is given to previously unaddressed questions and challenging concepts.
The scope of ASPIRE Awards includes:
- Basic Research:
- Projects that have the potential to substantially accelerate understanding of cancer disease mechanisms and pathophysiology
- Therapeutic Discovery and Translational Science:
- Projects that include initial investigations of novel concepts in cancer therapeutics and/or that seek to answer key translational science questions on the critical path to the clinic
- Innovative Technologies:
- Projects aimed at developing innovative technology solutions that are integrated with leading-edge concepts in cancer biology
- Clinical Research:
- Projects involving biomarker-rich, early-stage clinical trials and correlative studies that address fundamental questions related to the interplay of cancer therapy, intervention and/or companion diagnostics and biology
Award Terms
- The budget and duration requested for the grant must match a realistic estimate of the cost and timeline for the proposed work, with standard awards defined as:
- ASPIRE I Awards for periods of 12 months or less with total budgets up to $250,000 (up to 24 months and $500,000 allowed for clinical studies)
- ASPIRE II Awards for periods of 36 months or less with total budgets up to $750,000 (larger amounts will be considered for clinical studies)
- Projects typically start as an ASPIRE I; those that successfully demonstrate feasibility or proof of concept may be invited to apply for an ASPIRE II to further develop and expand the research
- In unique circumstances, by invitation only, investigators may be invited to start with an ASPIRE II Award
- The budget limit includes both direct and indirect costs, with indirect costs not to exceed 10% of the direct costs
- Co-investigators are permitted
- Revenue sharing terms will apply
- Additional considerations for clinical research awards:
- No more the 25% of the total budget may be used to defray clinical trial costs such as research nurses, data management, IRB fees, and database development
- Funds will not be released until the protocol has necessary institutional approvals
Eligibility
_You can learn more about this opportunity by visiting the funder's website._
- ASPIRE Awards support research worldwide, and collaborations are within the scope of the funding mechanism
- Principal investigators must be independent researchers at their respective institutions
- The budget limit includes both direct and indirect costs, with indirect costs not to exceed 10% of the direct costs
- Co-investigators are permitted
- Revenue sharing terms will apply
- Additional considerations for clinical research awards:
- No more the 25% of the total budget may be used to defray clinical trial costs such as research nurses, data management, IRB fees, and database development
- Funds will not be released until the protocol has necessary institutional approvals
What The Mark Foundation for Cancer Research (US) Ltd actually gave
Source: IRS Form 990, 2024
- Grants in 2024
- 29
- Total given
- $19.49M
- Median grant
- $500K
- Range
- $11K–$2.75M
- By dollars: New York 32%, California 27%, Massachusetts 9%. Top recipient cities: New York, NY; Boston, MA; San Francisco, CA.
- 0% of grants with a stated purpose were for general or operating support.
- 21% of recipients were new grantees, not repeat recipients.
Example grants
The Trustees of Columbia University in the City of New York · New York, NY
Research
$2.75M
Regents of the University of California San Francisco · San Francisco, CA
Research
$2.3M
Memorial Sloan Kettering Cancer Center · New York, NY
Research
$1.57M
Johns Hopkins University · Baltimore, MD
Research
$1.38M
The Salk Institute for Biological Studies · La Jolla, CA
Research
$1M
Focus Areas & Funding Uses
Fields of Work
- Cancer
- Science research
Categories
Browse similar grants by category
Related Grants
Open grants from this funder and similar programs
Endeavor Award
The Mark Foundation for Cancer Research (US) Ltd
Amount
Varies
Deadline
Deadline not published
Emerging Leader Award Grant
The Mark Foundation for Cancer Research (US) Ltd
Amount
Varies
Deadline
Deadline not published
Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)
National Institutes of Health
Amount
Up to $350,000
Deadline
November 6, 2026
Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
National Institutes of Health
Amount
$50,000 - $300,000
Deadline
November 10, 2026
Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
National Institutes of Health
Amount
$50,000 - $150,000
Deadline
November 10, 2026
Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)
National Institutes of Health
Amount
Up to $200,000
Deadline
November 17, 2026
Ready to apply for ASPIRE Awards?
Grantable helps you assess fit, draft narratives, and track deadlines — so you can submit stronger applications, faster.
You found ASPIRE Awards. Now let's win it.